Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.00
Bid: 1,773.00
Ask: 1,773.50
Change: 12.00 (0.68%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,773.50
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Energy, healthcare stocks lift FTSE 100; BHP Group shines

Tue, 17th Aug 2021 09:46

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* UK employment closer to pre-pandemic levels

* BHP Group jumps on strong results

* PLUS500 gains on robust revenue forecasts

* FTSE 100 up 0.3%, FTSE 250 off 0.2%
(Updates to close)

By Shashank Nayar and Amal S

Aug 17 (Reuters) - London's FTSE 100 rose on Tuesday, helped
by gains in heavyweight energy and healthcare stocks, with
sentiment bolstered by robust earnings from BHP Group and
employment numbers that showed a steady economic recovery in the
UK.

After falling as much as 0.5%, the blue-chip FTSE 100 index
ended 0.3% higher, helped by oil majors BP and
Royal Dutch Shell as crude prices recouped early
losses.

Healthcare stocks rose 1.1% with drugmakers
including AstraZeneca, GlaxoSmithKline, and
Hikma Pharmaceuticals rising between 1% and 2.3%.

Miner BHP Group gained 3.1% to the top of the FTSE
100 after posting its best annual profit in nearly a decade. It
also announced an exit from its $13 billion petroleum business
in a portfolio shake-up that will see it leave London's FTSE 100
index.

"BHP has a clear strategy now of focusing on future-proofed
commodities which are part of the transition away from fossil
fuels or in other words being part of the solution rather than
part of the problem and it's an approach which is winning favour
from the market," said Russ Mould, investment director at AJ
Bell.

Steadily rising commodity prices and cheap interest rates
have helped the FTSE 100 rise nearly 11% year-to-date, but
inflation pressure, risks linked to the coronavirus pandemic and
less weightage of tech stocks on the index have led it to
underperform developed-market peers.

The number of employees on British company payrolls rose by
182,000 in July from June, moving closer to their pre-pandemic
level as the economy recovers from its coronavirus lockdowns,
tax data showed.

Unemployment in the UK dropped to 4.7% in the three months
to June, lower than economist expectations of 4.8%.

The domestically focussed mid-cap index eased 0.2%,
with travel stocks declining the most.

Online trading platform Plus500 jumped 5.1% to the
top of the mid-cap index after it forecast annual revenue
"significantly ahead" of analysts' estimates.

UK-listed shares of food-ordering firm Just Eat Takeaway.com
gained 2.9% and was the second-best performer on FTSE
100, after it reported a better-than-expected operating loss of
190 million euros ($224 million) for the first half of
2021.
(Reporting by Shashank Nayar and Amal S in Bengaluru; Editing
by Subhranshu Sahu and Uttaresh.V and Bernadette Baum)

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.